Skip to main content
SupplementScience

Sulbutiamine Research & Evidence

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Emerging

Sulbutiamine was developed in Japan and gained clinical use in France as Arcalion for asthenia. Its pharmacological profile — superior BBB penetration, dopaminergic modulation, and cholinergic potentiation — has been characterized in preclinical studies (Micheau et al., 1985). Clinical data is limited to small trials and post-marketing surveillance from its use as Arcalion. Its anti-fatigue effects are the most clinically validated benefit. The nootropic community values it primarily for motivation enhancement via dopamine receptor upregulation.

Evidence by Condition

ConditionStudied DoseEvidence
Mental fatigue400-600mg dailyEmerging
Cognitive enhancement400mg dailyEmerging
Motivation and drive600mg dailyPreliminary
Full Sulbutiamine Guide

References

  1. (). Chronic administration of sulbutiamine improves long term memory formation in mice: possible cholinergic mediation. Pharmacology Biochemistry and Behavior. DOI
  2. (). Treatment of chronic postinfectious fatigue: randomized double-blind study of two doses of sulbutiamine (400-600 mg/day) versus placebo. La Revue de Médecine Interne. DOI
  3. (). Clinical efficacy of the drug sulbutiamine in the treatment of erectile dysfunction in patients with psychogenic and mixed organic etiology. Urologiia.